Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, UK.
Department of Paediatric Endocrinology, Barts Health NHS Trust, London, UK.
Endocr Relat Cancer. 2022 Sep 7;29(11):G1-G33. doi: 10.1530/ERC-22-0035. Print 2022 Nov 1.
This guideline is written as a reference document for clinicians presented with the challenge of managing paediatric patients with differentiated thyroid carcinoma up to the age of 19 years. Care of paediatric patients with differentiated thyroid carcinoma differs in key aspects from that of adults, and there have been several recent developments in the care pathways for this condition; this guideline has sought to identify and attend to these areas. It addresses the presentation, clinical assessment, diagnosis, management (both surgical and medical), genetic counselling, follow-up and prognosis of affected patients. The guideline development group formed of a multi-disciplinary panel of sub-speciality experts carried out a systematic primary literature review and Delphi Consensus exercise. The guideline was developed in accordance with The Appraisal of Guidelines Research and Evaluation Instrument II criteria, with input from stakeholders including charities and patient groups. Based on scientific evidence and expert opinion, 58 recommendations have been collected to produce a clear, pragmatic set of management guidelines. It is intended as an evidence base for future optimal management and to improve the quality of clinical care of paediatric patients with differentiated thyroid carcinoma.
本指南旨在为临床医生提供参考,帮助他们应对 19 岁以下分化型甲状腺癌患儿的管理挑战。儿科分化型甲状腺癌患者的护理在关键方面与成人不同,该疾病的护理路径也有了一些新的进展;本指南旨在确定并关注这些领域。它涉及到患者的表现、临床评估、诊断、管理(包括手术和药物治疗)、遗传咨询、随访和预后。指南制定小组由多个亚专科专家组成,进行了系统的原始文献回顾和德尔菲共识研究。该指南是根据《评估指南研究和评估工具 II 标准》制定的,利益相关者(包括慈善机构和患者团体)也提供了意见。基于科学证据和专家意见,共收集了 58 条建议,制定了一套清晰、实用的管理指南。本指南旨在为未来的最佳管理提供依据,并提高儿科分化型甲状腺癌患儿的临床护理质量。